Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Fmr LLC

FMR LLC raised its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 675.9% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 586,902 shares of the company's stock after purchasing an additional 511,256 shares during the period. FMR LLC owned 0.83% of Nurix Therapeutics worth $13,188,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NRIX. Amalgamated Bank lifted its holdings in Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company's stock valued at $49,000 after purchasing an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock worth $54,000 after acquiring an additional 559 shares during the period. International Assets Investment Management LLC raised its holdings in shares of Nurix Therapeutics by 1,098.4% during the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company's stock worth $101,000 after acquiring an additional 4,119 shares during the period. Quest Partners LLC raised its holdings in shares of Nurix Therapeutics by 21.3% during the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after acquiring an additional 1,312 shares during the period. Finally, Dark Forest Capital Management LP purchased a new position in shares of Nurix Therapeutics during the 2nd quarter worth $201,000.

Analyst Ratings Changes

NRIX has been the topic of several analyst reports. HC Wainwright lifted their price target on Nurix Therapeutics from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday. Oppenheimer lifted their price target on Nurix Therapeutics from $27.00 to $30.00 and gave the stock an "outperform" rating in a report on Wednesday, September 4th. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a report on Friday, October 11th. They set a "buy" rating and a $41.00 price target on the stock. Needham & Company LLC reissued a "buy" rating and set a $29.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday. Finally, UBS Group started coverage on Nurix Therapeutics in a research report on Thursday, October 24th. They issued a "buy" rating and a $35.00 target price for the company. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $30.35.

Nurix Therapeutics Trading Down 3.2 %

NRIX stock traded down $0.69 during trading on Thursday, hitting $20.62. 556,232 shares of the company's stock were exchanged, compared to its average volume of 902,830. The business has a 50-day moving average price of $23.70 and a two-hundred day moving average price of $22.10. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -7.32 and a beta of 2.11. Nurix Therapeutics, Inc. has a 52-week low of $7.65 and a 52-week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The company had revenue of $12.59 million during the quarter, compared to analysts' expectations of $13.85 million. On average, equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 2,368 shares of the business's stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $57,542.40. Following the transaction, the chief financial officer now owns 37,270 shares of the company's stock, valued at approximately $905,661. The trade was a 5.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Christine Ring sold 3,290 shares of the business's stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $25.00, for a total value of $82,250.00. Following the completion of the transaction, the insider now directly owns 24,592 shares in the company, valued at approximately $614,800. The trade was a 11.80 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,401 shares of company stock worth $437,453. 7.20% of the stock is owned by insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.